Home › Funds › ELKHORN PARTNERS LIMITED PARTNERSHIP › CRDF
ELKHORN PARTNERS LIMITED PARTNERSHIP position in CRDF
CARDIFF ONCOLOGY INC · Health Care
ELKHORN PARTNERS LIMITED PARTNERSHIP reported holding 48,000 shares of CRDF (CARDIFF ONCOLOGY INC) in its Q3 2026 13F filing — a position valued at US$58K, representing 0.05% of its reported portfolio and ranking #36 among its reported holdings. ELKHORN PARTNERS LIMITED PARTNERSHIP has disclosed CRDF holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How ELKHORN PARTNERS LIMITED PARTNERSHIP's CRDF position evolved
ELKHORN PARTNERS LIMITED PARTNERSHIP first disclosed a stake in CRDF in Q3 2023 at 45,000 shares (US$63K). The position peaked in Q1 2024 at 39,000 shares, worth US$208K. Across 13 filings, ELKHORN PARTNERS LIMITED PARTNERSHIP increased the stake 8 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 48,000 shares valued at US$58K. Notable position changes include a 46% increase in Q4 2023 (shares rose 261% over the following quarter), a 40% trim in Q1 2024 (shares fell 58% over the following quarter), a 29% trim in Q4 2024 (shares fell 28% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 45.00K | $63.00K | New |
| Q4 2023 | 65.50K | $97.00K | Add |
| Q1 2024 | 39.00K | $208.00K | Reduce |
| Q2 2024 | 41.00K | $91.00K | Add |
| Q3 2024 | 45.00K | $120.00K | Add |
| Q4 2024 | 32.00K | $139.00K | Reduce |
| Q1 2025 | 32.50K | $102.00K | Add |
| Q2 2025 | 34.00K | $107.10K | Add |
| Q3 2025 | 39.00K | $80.34K | Add |
| Q4 2025 | 38.10K | $107.06K | Reduce |
| Q1 2026 | 44.50K | $72.09K | Add |
| Q2 2026 | 48.00K | $62.40K | Add |
| Q3 2026 | 48.00K | $58.08K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRDF and 13F data
CRDF (CARDIFF ONCOLOGY INC) is a Health Care company. 22 other funds we track also report a position in CRDF — the largest reported positions include PFIZER INC (US$3.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
More on ELKHORN PARTNERS LIMITED PARTNERSHIP
FAQ
How long has ELKHORN PARTNERS LIMITED PARTNERSHIP held CRDF?
ELKHORN PARTNERS LIMITED PARTNERSHIP has disclosed CRDF holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is ELKHORN PARTNERS LIMITED PARTNERSHIP's current position in CRDF?
As of Q3 2026, ELKHORN PARTNERS LIMITED PARTNERSHIP holds 48.00K shares of CRDF (CARDIFF ONCOLOGY INC), valued at $58.08K, representing 0.05% of its reported portfolio and ranking #36.
Has ELKHORN PARTNERS LIMITED PARTNERSHIP been buying or selling CRDF?
In the latest 13F filing (Q3 2026), ELKHORN PARTNERS LIMITED PARTNERSHIP held unchanged its position in CRDF. The position peaked in Q1 2024 at 39.00K shares.
Which other funds hold CRDF?
Other major institutional holders of CRDF include PFIZER INC, among 22 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.